DXCM DEXCOM INC.

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--

(NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.

The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast.

Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference.

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit .

Category: IR

EN
07/01/2025

Underlying

DXCMDEXCOM INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter a...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310 million, an increase of 17% over the fourth quarter of 2023. For fiscal 2024, total preliminary, unaudited revenue is approximately $4.032 billion, an increase of 11% over 2...

January 13, 2025 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the sta...

January 7, 2025 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. , the first over-the-counter glucose biosensor cleared2 by the FDA in the United States, is the first Dexcom product...

December 17, 2024 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Alberta Government Lifts Age Restrictions on Continuous Glucose Monito...

BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older. This press release features multimedia. View the full release here: Alberta residents living with type 1 or type 2 diabetes who meet the eligibility criteria are now covered for Dexcom G7 (Photo: Business Wire) Alberta res...

December 17, 2024 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom and ŌURA Announce Strategic Partnership

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in glucose biosensing, and , maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combining Dexcom glucose data with the biometrics collected by Oura Ring will provide users of both products with a more complete picture of overall health. Dexcom is also making a $75 million strategic investment in ŌURA Serie...

November 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch